INmune Bio (INMB) Projected to Post Quarterly Earnings on Thursday

INmune Bio (NASDAQ:INMB) is anticipated to issue its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($0.27) per share for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, April 2, 2026 at 4:00 PM ET.

INmune Bio Stock Performance

Shares of INmune Bio stock opened at $1.24 on Tuesday. The firm has a market capitalization of $32.96 million, a price-to-earnings ratio of -0.58 and a beta of 0.77. INmune Bio has a fifty-two week low of $1.15 and a fifty-two week high of $11.64. The stock has a 50 day moving average of $1.45 and a 200 day moving average of $1.67.

Institutional Investors Weigh In On INmune Bio

Institutional investors have recently modified their holdings of the company. Rhumbline Advisers boosted its holdings in INmune Bio by 14.4% during the 1st quarter. Rhumbline Advisers now owns 19,153 shares of the company’s stock valued at $150,000 after acquiring an additional 2,409 shares during the period. Charles Schwab Investment Management Inc. increased its stake in INmune Bio by 20.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 50,252 shares of the company’s stock worth $78,000 after purchasing an additional 8,427 shares during the period. Royal Bank of Canada lifted its position in shares of INmune Bio by 44.8% during the first quarter. Royal Bank of Canada now owns 29,863 shares of the company’s stock worth $233,000 after purchasing an additional 9,236 shares in the last quarter. Wells Fargo & Company MN lifted its position in shares of INmune Bio by 79.0% during the fourth quarter. Wells Fargo & Company MN now owns 24,857 shares of the company’s stock worth $39,000 after purchasing an additional 10,970 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new position in shares of INmune Bio in the second quarter valued at approximately $26,000. 12.72% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Lucid Cap Mkts raised INmune Bio from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 11th. Wall Street Zen upgraded shares of INmune Bio from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $8.00.

About INmune Bio

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.